Cargando…

Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1

OBJECTIVES: The aim of this study was to assess soluble CD30 (sCD30), a protein that colocalises with HIV-1 RNA and DNA in lymphoid cells and tissues, in cerebrospinal fluid (CSF) as a marker of HIV-1 infection in the central nervous system (CNS). METHODS: This was a cross-sectional study using arch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peluso, Michael J, Thanh, Cassandra, Prator, Cecilia A, Hogan, Louise E, Arechiga, Victor M, Stephenson, Sophie, Norris, Philip J, Di Germanio, Clara, Fuchs, Dietmar, Zetterberg, Henrik, Deeks, Steven G, Gisslén, Magnus, Price, Richard W, Henrich, Timothy J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mediscript Ltd 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043898/ https://www.ncbi.nlm.nih.gov/pubmed/32175087

Ejemplares similares

Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression
por: Gisslen, Magnus, et al.
Publicado: (2021)

Elevated Cerebrospinal Fluid Anti-CD4 Autoantibody Levels in HIV Associate with Neuroinflammation
por: Cheng, Da, et al.
Publicado: (2022)

Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy
por: Gisslén, Magnus, et al.
Publicado: (2012)

Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy
por: Yilmaz, Aylin, et al.
Publicado: (2013)

Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection
por: Gisslén, Magnus, et al.
Publicado: (2005)

Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study
por: Jespersen, Sofie, et al.
Publicado: (2016)

Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders
por: Yilmaz, Aylin, et al.
Publicado: (2019)

Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection
por: Anesten, Birgitta, et al.
Publicado: (2021)

Correction: Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection
por: Anesten, Birgitta, et al.
Publicado: (2022)

Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection
por: Hermansson, Linn, et al.
Publicado: (2019)

Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection
por: Peterson, Julia, et al.
Publicado: (2014)

Cerebrospinal Fluid Viral Load and Intrathecal Immune Activation in Individuals Infected with Different HIV-1 Genetic Subtypes
por: Abdulle, Sahra, et al.
Publicado: (2008)

Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia – case report
por: Andersson, Lars-Magnus, et al.
Publicado: (2006)

CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection
por: Gisslén, Magnus, et al.
Publicado: (2018)

Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection
por: Price, Richard W., et al.
Publicado: (2013)

Herpes zoster in HIV-1 infection: The role of CSF pleocytosis in secondary CSF escape and discordance
por: Hagberg, Lars, et al.
Publicado: (2020)

Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection
por: Hagberg, Lars, et al.
Publicado: (2010)

The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease
por: Mäkitalo, Signar, et al.
Publicado: (2015)

A High Percentage of People With Human Immunodeficiency Virus (HIV) on Antiretroviral Therapy Experience Detectable Low-Level Plasma HIV-1 RNA Following Coronavirus Disease 2019 (COVID-19)
por: Peluso, Michael J, et al.
Publicado: (2020)

Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection
por: Ahlgren, Erika, et al.
Publicado: (2016)

Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study
por: Yilmaz, Aylin, et al.
Publicado: (2006)

Residual Central Nervous System Immune Activation Is Not Prevented by Antiretroviral Therapy Initiated During Early Chronic HIV Infection
por: Edén, Arvid, et al.
Publicado: (2023)

Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients
por: Ferretti, Francesca, et al.
Publicado: (2016)

High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal Fluid
por: Booiman, Thijs, et al.
Publicado: (2017)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Cerebrospinal fluid HIV infection and pleocytosis: Relation to systemic infection and antiretroviral treatment
por: Spudich, Serena S, et al.
Publicado: (2005)

Composition and Function of T Cell Subpopulations Are Slow to Change Despite Effective Antiretroviral Treatment of HIV Disease
por: Emu, Brinda, et al.
Publicado: (2014)

Blood–brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV
por: Anesten, Birgitta, et al.
Publicado: (2016)

Cohort profile: a longitudinal study of HIV infection in the central nervous system with focus on cerebrospinal fluid – the Gothenburg HIV CSF Study Cohort
por: Hagberg, Lars, et al.
Publicado: (2023)

Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms
por: Edén, Arvid, et al.
Publicado: (2022)

Biomarker Evidence of Axonal Injury in Neuroasymptomatic HIV-1 Patients
por: Jessen Krut, Jan, et al.
Publicado: (2014)

Sex difference in circulating soluble form of ACE2 protein in moderate and severe COVID-19 and healthy controls
por: Robertson, Josefina, et al.
Publicado: (2022)

LB8. Lower SARS-CoV-2 IgG and Pseudovirus Neutralization Titers Post-mRNA Vaccination among People Living with HIV
por: Spinelli, Matthew A, et al.
Publicado: (2021)

Blood and cerebrospinal fluid biomarker changes in patients with HIV-associated neurocognitive impairment treated with lithium: analysis from a randomised placebo-controlled trial
por: Thela, Lindokuhle, et al.
Publicado: (2023)

Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection
por: Yilmaz, Aylin, et al.
Publicado: (2009)

Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
por: Heslegrave, Amanda, et al.
Publicado: (2016)

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
por: Gisslén, Magnus, et al.
Publicado: (2015)

Corrigendum to: “Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study” [EBioMedicine 3 (216) 135–140]
por: Gisslén, Magnus, et al.
Publicado: (2016)

Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID‐19
por: Apple, Alexandra C., et al.
Publicado: (2022)

Serum neopterin levels in relation to mild and severe COVID-19
por: Robertson, Josefina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bqgfvfc1fe5o9irmuheu7dn2dk